Heart regeneration therapy by autologous Adipose Tissue Derived Stromal Cells

Clinical trial of autologous adiose tissue derived stromal cell therapy for ischemic heart failure - ADRC-IHF

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTb040190115

Enrollment

Registered

2020-02-12

Start date

2013-04-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart failure that occurred by prior ischemic event whose ejection fraction is less than 40%

Interventions

Intracoronary administration of autologus adipose tissue derived regenerative cells

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Heart failure that occurred by prior ischemic event whose ejection fraction is less than 40%

Exclusion criteria

Exclusion criteria: 1.Complicated severe other organ disease. 2.Patients with malignancy. 3.History of chemotherapy or irradiation within 4 weeks. 4.Patients with immunodeficiency 5.Pregnancy or possibility of pregnancy 6.Candidates who are judged to be not applicable to this study by doctors.

Design outcomes

Primary

Measure	Time frame
Safety at a perioperative period and 6 months in the context of adverse events defined in the implementation protocol	—

Secondary

Measure	Time frame
1. Left ventricular ejection fraction (LVEF) by echocardiography and Tc99m-SPECT or cardiac MR at 6 months 2. Myocardial perfusion (Tc99m-SPECT) at 6 months	—

Countries

Japan

Contacts

Public ContactShinichiro Takashima

Kanazawa University Hospital

takashin@m-kanazawa.jp+81-76-265-2259

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026